Background
Earlier DSIP sleep research had largely relied on intracerebroventricular (ICV) administration, limiting its clinical translational relevance. Bjorvatn and Ursin’s study at the University of Bergen examined whether systemically administered DSIP — via IV and SC routes more relevant to clinical use — could still produce sleep EEG effects, and if so, at which sleep stages.
This work addressed a key question in DSIP research: does the peptide retain activity when administered peripherally, given its susceptibility to enzymatic degradation in blood?
Methods
Male Sprague-Dawley rats implanted with chronic EEG and EMG electrodes were administered:
- DSIP at 3, 10, and 30 nmol/kg IV or SC
- Vehicle control (saline, IV or SC)
Sleep was recorded continuously for 6 hours post-injection and scored into:
- Waking
- SWS-1 (light slow-wave sleep)
- SWS-2 (deep slow-wave/delta sleep)
- REM sleep
Key Findings
Slow-wave sleep enhancement:
- DSIP (10 and 30 nmol/kg IV) significantly increased SWS-2 time in hours 1–3 post-injection
- SWS-2 increase: ~18–22% above vehicle at 10 nmol/kg IV
- SC administration required higher doses for comparable effects, consistent with reduced bioavailability
Stage specificity:
- Effect was selective for SWS-2 (deep delta sleep); SWS-1 (light NREM) was not significantly changed
- REM sleep: no significant change in total duration or latency
- Sleep onset latency: not significantly affected
Dose-response:
- 3 nmol/kg produced a trend but did not reach significance for SWS-2
- 30 nmol/kg showed similar magnitude to 10 nmol/kg, suggesting a ceiling effect at this dose range
Time course:
- Sleep effects concentrated in hours 1–3; hours 3–6 showed normalization toward baseline
- No rebound suppression of SWS-2 in the later recording period
Clinical Significance
This study confirmed that DSIP retains sleep-promoting activity when administered systemically — a prerequisite for any clinical application. The selectivity for deep delta (SWS-2) sleep is particularly relevant because:
- SWS-2 is the most restorative sleep stage, characterized by highest GH secretion, muscle repair signaling, and memory consolidation
- Existing hypnotics (benzodiazepines, Z-drugs) suppress SWS-2, making DSIP’s mechanism mechanistically distinct and potentially superior for recovery applications
- No REM suppression avoids the cognitive and emotional processing impairments associated with REM-suppressing sedatives
Limitations
- Rat model only; rodent sleep architecture differs from humans (polyphasic, different cycle lengths)
- SC bioavailability was lower and more variable — chronic SC dosing in humans would require further PK characterization
- Long-term administration effects on sleep homeostasis and tolerance were not assessed
- Mechanism by which peripheral DSIP reaches CNS targets despite peptidase activity is not resolved